

# Maintenance of World Health Organization Risk Drinking Posttreatment Functioning Following a Large Alcohol U

Alcoholism: Clinical and Experimental Research  
43, 979-987

DOI: [10.1111/acer.14018](https://doi.org/10.1111/acer.14018)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Response to Dr. Mark Litt's Commentary. Alcoholism: Clinical and Experimental Research, 2019, 43, 2255-2256.	2.4	0
2	Clinical validation of reduction in cocaine frequency level as an endpoint in clinical trials for cocaine use disorder. Drug and Alcohol Dependence, 2019, 205, 107648.	3.2	27
3	Prevalence of risk "drinking in critically ill patients, screened with carbohydrate-deficient transferrin and AUDIT-C score: A retrospective study. Acta Anaesthesiologica Scandinavica, 2020, 64, 216-223.	1.6	3
4	Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice. Alcoholism: Clinical and Experimental Research, 2020, 44, 23-35.	2.4	17
5	"The post-COVID era" challenges in the treatment of substance use disorder (SUD) after the pandemic. BMC Medicine, 2020, 18, 241.	5.5	44
6	Not All Is Lost for Relapsers: Relapsers With Low WHO Risk Drinking Levels and Complete Abstainers Have Comparable Regional Gray Matter Volumes. Alcoholism: Clinical and Experimental Research, 2020, 44, 1479-1487.	2.4	13
7	Evidence based models of care for the treatment of alcohol use disorder in primary health care settings: a systematic review. BMC Family Practice, 2020, 21, 260.	2.9	9
8	A review of performance indicators of single-item alcohol screening questions in clinical and population settings. Journal of Substance Abuse Treatment, 2020, 111, 73-85.	2.8	6
9	World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom. Addiction, 2020, 115, 1668-1680.	3.3	44
10	Reconsidering alcohol treatment non-responders: psychosocial functioning among heavy drinkers 3 years following treatment. Addiction, 2021, 116, 1262-1269.	3.3	5
11	Stability of Drinking Reductions and Long-term Functioning Among Patients with Alcohol Use Disorder. Journal of General Internal Medicine, 2021, 36, 404-412.	2.6	12
12	Recovery from addiction: A synthesis of perspectives from behavioral economics, psychology, and decision modeling. , 2021, , 563-579.		3
13	Taking social identity into practice. , 2021, , 511-530.		1
14	Narrative review of hepatocellular carcinoma: from molecular bases to therapeutic approach. Digestive Medicine Research, 0, 4, 15-15.	0.2	1
15	Stability of Posttreatment Reductions in World Health Organization (WHO) Drinking Risk Levels and Posttreatment Functioning in Older Adults with DSM-5 Alcohol Use Disorder: Secondary Data Analysis of the Elderly Study. Alcoholism: Clinical and Experimental Research, 2021, 45, 638-649.	2.4	4
16	The World Health Organization Risk Drinking Levels Measure of Alcohol Consumption: Prevalence and Health Correlates in Nationally Representative Surveys of U.S. Adults, 2001-2002 and 2012-2013. American Journal of Psychiatry, 2021, 178, 548-559.	7.2	20
17	Predictors of early and sustained cessation of heavy drinking over 5 years among adult primary care patients. Addiction, 2022, 117, 82-95.	3.3	4
18	World Health Organization risk drinking levels as a treatment outcome measure in topiramate trials. Alcoholism: Clinical and Experimental Research, 2021, 45, 1664-1671.	2.4	7

#	ARTICLE	IF	CITATIONS
19	The relationship of frequency of cocaine use to substance and psychiatric disorders in the U.S. general population. <i>Drug and Alcohol Dependence</i> , 2021, 227, 108933.	3.2	3
20	The "alcoholic other": Harmful drinkers resist problem recognition to manage identity threat. <i>Addictive Behaviors</i> , 2022, 124, 107093.	3.0	20
21	SF-36 utility scores for alcohol use disorder status and alcohol consumption risk levels in the US population. <i>Addiction</i> , 2021, 116, 1034-1042.	3.3	8
22	Sex Differences in the Neurobiology of Alcohol Use Disorder. <i>Alcohol Research: Current Reviews</i> , 2020, 40, 04.	3.6	56
23	New Australian guidelines for the treatment of alcohol problems: an overview of recommendations. <i>Medical Journal of Australia</i> , 2021, 215, S3-S32.	1.7	34
26	Biopsychosocial Process of Change in Alcohol Use Disorder Recovery. , 2021, , 25-40.		0
27	Dose of psychotherapy and long-term recovery outcomes: An examination of attendance patterns in alcohol use disorder treatment.. <i>Journal of Consulting and Clinical Psychology</i> , 2021, 89, 1026-1034.	2.0	6
28	Barriers and Facilitators to Changing Drinking and Receiving Alcohol-Related Care: Interviews with Veterans Health Administration Primary Care Patients who Indicated Interest but Did Not Enroll in An Alcohol Care Management Intervention Trial. <i>Substance Abuse</i> , 2022, 43, 1197-1206.	2.3	4
29	Inhibition of reinstatement of alcohol-induced conditioned place preference in mice by <i>Lonicera japonica</i> polysaccharide. <i>Food and Function</i> , 2022, 13, 8643-8651.	4.6	2
30	Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 2258-2266.	2.4	0
31	Deep brain stimulation of the nucleus accumbens in treatment-resistant alcohol use disorder: a double-blind randomized controlled multi-center trial. <i>Translational Psychiatry</i> , 2023, 13, .	4.8	10
33	Should we promote alcohol problems as a continuum? Implications for policy and practice. <i>Drugs: Education, Prevention and Policy</i> , 0, , 1-11.	1.3	5
34	Resting state functional connectivity as a predictor of brief intervention response in adults with alcohol use disorder: A preliminary study. , 2023, 47, 1590-1602.		0
35	Non-abstinent recovery in alcohol use disorder is associated with greater regional cortical volumes than heavy drinking. , 2023, 47, 1850-1858.		1
36	The Clinical Benefits of Non-abstinent Outcomes in Alcohol Use Disorder Treatment: Evidence from Clinical Trials and Treatment Implications. , 2023, , 341-364.		0
37	Reductions in WHO risk drinking levels correlate with alcohol craving among individuals with alcohol use disorder. , 2024, 48, 420-429.		0
38	Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials. <i>Addiction</i> , 2024, 119, 833-843.	3.3	1
39	Regional cortical brain volumes at treatment entry relates to post treatment WHO risk drinking levels in those with alcohol use disorder. <i>Drug and Alcohol Dependence</i> , 2024, 255, 111082.	3.2	0

#	ARTICLE	IF	CITATIONS
40	Alcohol Use Disorder Treatment: Problems and Solutions. Annual Review of Pharmacology and Toxicology, 2024, 64, 255-275.	9.4	0
41	Untangling pathways of risk factors associated with hypertension among dysglycemia adults in eastern China: a structural equation model approach. Acta Diabetologica, 2024, 61, 587-597.	2.5	0